Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments

[at noodls] – Upcoming Meetings With FDA Will Determine Fastest Path to Pursue Eteplirsen Approval; Additional Drugs for Duchenne Muscular Dystrophy (DMD) Continue to Progress Through Preclinical Development; 2013 Financial … more

View todays social media effects on SRPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Sarepta is hiring next, click here to view